New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
08:11 EDTGHDXGenomic Health's Oncotype DX colon cancer survey shows positive impact
Genomic Health announced results from the Oncotype DX colon cancer test studies highlighting the body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions. Through an analysis of physician recommendations and patient treatment preferences before and after receiving the Oncotype DX colon cancer test results, this study demonstrated that the test increased concordance between physician and patient treatment choice from 66% to 96%, that the quantitative information provided by the Recurrence Score result influenced a majority of patients' treatment decisions and physicians' treatment recommendations, and increased physicians' confidence in their own recommendations. Patients' anxiety was also significantly reduced, which may improve adherence to their treatment plan and ultimately lead to better health outcomes.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:55 EDTGHDXGenomic Health remains a top pick, says Cowen
Cowen noted Genomic Health reported in-line Q4 results, but said with the recent price depreciation the shares are increasingly attractive and remain a top pick. Cowen reiterated its Outperform rating and $40 price target on Genomic Health.
February 10, 2016
16:18 EDTGHDXGenomic Health sees FY16 EPS (55c)-(37c), consensus (13c)
Sees FY16 revenue $320M-$335M, consensus $328.76M. Sees FY16 Oncotype DX tests delivered of 117,500 to 121,000, representing growth of between 10%-13% compared to 2015.
16:17 EDTGHDXGenomic Health reports Q4 EPS (10c), consensus (9c)
Reports Q4 revenue $74.5M, consensus $74.87M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use